101

About this trial

Last updated 2 years ago

Study ID

101

Status

Recruiting

Type

Observational

Placebo

Accepting

50 to 85 Years

All

Not accepting

Healthy Volunteers

Trial Timing

Ended a year ago

The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.

Inclusion Criteria

1. Men and women 50 to 85 years of age

2. Clinical diagnosis of mild cognitive impairment, and a presumed etiology of DLB or AD at enrollment

Exclusion Criteria

1. Clinical evidence of severe peripheral vascular disease (Fazekas score of ≥ 3, or a large vessel stroke of ≥ 2 cm, history of ulceration, poor wound healing, vascular claudication)

2. Clinically active coronary artery or cerebrovascular disease

3. Current smoker or alcoholism

4. History of allergic reaction to local anesthesia (for biopsy collection)

5. Use of anticoagulants (aspirin or Plavix alone is allowed)

6. Significantly impaired wound healing or history of scarring or keloid formation